Search 

OBN is the membership organisation supporting and bringing together the UK's emerging life science companies, corporate partners and investors. Our 380+ member companies are located across the Golden Triangle and beyond, and benefit from our networking, partnering, purchasing, advising, and advocacy activities. OBN organises BioTrinity - Europe's Leading Investment and Biopartnering Conference attracting over 1000 delegates (April 23-25, 2018).

Oncimmune is a biotech company that specialises in blood tests and services that make use of the immune system. The EarlyCDT blood tests can detect cancer in the earliest stages when the body’s immune system is trying to fight it. The Company’s understanding of the immune system also means they’re able to work closely with pharmaceutical companies to ensure treatments, such as immunotherapy, are as effective and safe as possible.

EarlyCDT Lung is the world’s most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor’s surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).